Tuberculosis (TB) still imposes a huge burden of ill health, premature deat
h and emotional suffering on the developing world. Over the past 30 y it ha
s been greatly neglected by those concerned about international public heal
th and there are now nearly 8 million new cases annually and 1.86 million d
eaths. An epidemic of HIV-associated TB is now affecting Africa and threate
ning parts of Asia. Multidrug-resistant TB has emerged as a huge threat in
Russia and its former satellites. However, with the advent of the directly
observed treatment, short-course (DOTS) strategy in 1995, high-burden count
ries have started to seriously address the problem. Recent political commit
ment on the part of the rich nations, together with significant increases i
n funding from private foundations and great scientific advances in our und
erstanding of Mycobacterium tuberculosis, give rise to cautious optimism th
at TB will be controlled during this century.